A medical economic analysis of cancer chemotherapy for patients with advanced lung cancer.
Not Applicable
Recruiting
- Conditions
- ung cancer
- Registration Number
- JPRN-UMIN000042535
- Lead Sponsor
- kansai medical university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Between June, 2020 to December, 2022, anti-cancer drugs for patients with lung cancer hasn't been approved yet, or rescission of approval by Ministry of Health, Labor and Welfare, JAPA
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method compare incremental cost effectiveness ratio between each drug as 1st-line or 2nd-line chemotherapy including molecular target drugs, angiogenesis inhibitors and immune checkpoint inhibitors for improving prognosis in patients with advanced lung cancer.
- Secondary Outcome Measures
Name Time Method search for appropriate treatment in cost-effectiveness for patients with advanced lung cancer, according to each of histopathological type, driver mutation and expression of PD-L1.